Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate if omalizumab co-treatment may allow reintroduction of honey bee venom immunotherapy in patients with immunotherapy treatment failure due to systemic reactions.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University Clinic of Pulmonary and Allergic Diseases Golnik
• Treatments: Omalizumab

Criteria

Inclusion Criteria:

• severe anaphylactic reaction after honey-bee sting (Mueller grade III or IV) confirmed sensitization to honey-bee venom,

• honey-bee venom immunotherapy treatment failure due to systemic reactions.

Exclusion Criteria:

• systemic mastocytosis,

• pregnancy,

• use of beta-adrenergic blocking agents.